Holly Springs has emerged as a preferred location for the life sciences industry due to strategic planning and investment, making it an attractive site for companies looking to expand their operations.

This expansion not only signifies Genentech's commitment to the local economy but also reflects the ongoing growth and investment in North Carolina's life sciences sector, which has seen over $20 billion in investments since 2020.

Genentech has announced a significant investment of $700 million to establish a high-volume fill/finish manufacturing facility in Holly Springs, North Carolina, which is expected to create 420 jobs.

Local officials, including Wake County Board of Commissioners Chair Susan Evans, have praised Genentech's presence, highlighting its role in enhancing the region's status as a global hub for biotech research and manufacturing.

The project is backed by a Job Development Investment Grant (JDIG) approved by the Economic Investment Committee, with projections indicating it could boost the state's economy by over $3 billion within the next 12 years.

Genentech's investment reflects a broader trend of pharmaceutical companies expanding operations in Holly Springs, which has become a growing biotech hub, attracting major players like Amgen and CSL Seqirus.

The investment was made possible through collaboration among various local and state partners, including the Town of Holly Springs and the North Carolina Community College System, demonstrating a strong commitment to economic development.

Paul Bezy, Genentech's Global Leader of Roche’s High Volume Technical Operations, emphasized that Holly Springs was chosen for its attractive talent pool and quality of life, which are essential for the company's operations.

Genentech's CEO, Ashley Magargee, expressed gratitude to North Carolina state officials for their support and highlighted the facility's potential to enhance their manufacturing network and positively impact the local economy.

This investment aligns with a national trend among drugmakers responding to government incentives for domestic production, as seen with companies like Eli Lilly and Johnson & Johnson.

This new facility will play a crucial role in supporting Roche and Genentech's future portfolio of next-generation obesity medicines, with potential for expansion based on business needs and U.S. policy.

The facility will specialize in fill/finish biomanufacturing, focusing on the final stages of preparing biopharmaceutical products for distribution, which will diversify the local life sciences industry.